Patents by Inventor Ai Ching Lim

Ai Ching Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-17 receptor A antigen binding proteins
    Patent number: 10208122
    Abstract: Disclosed is an isolated human monoclonal antibody that specifically binds IL-17 Receptor A, or an IL-17 Receptor A binding fragment thereof, and inhibits IL-17A from binding and activating the receptor. The present disclosure also provides compositions and methods for treating diseases mediated by IL-17 Receptor A activation.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: February 19, 2019
    Assignee: AMGEN K-A, INC.
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • Methods and compositions relating to anti-IL-21 receptor antibodies
    Patent number: 10184002
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: January 22, 2019
    Assignee: AMGEN INC.
    Inventors: Marc A. Gavin, Ai Ching Lim
  • INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
    Publication number: 20180162926
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Application
    Filed: November 29, 2017
    Publication date: June 14, 2018
    Inventors: Yan CHEN, Elena GETMANOVA, Martin C. WRIGHT, Alan S. HARRIS, Ai Ching LIM, Jochem GOKEMEIJER, Lin SUN, Michael WITTEKIND
  • ST2 antigen binding proteins
    Patent number: 9982054
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: May 29, 2018
    Assignee: AMGEN INC.
    Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
  • Inhibitors of type 2 vascular endothelial growth factor receptors
    Patent number: 9862758
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: January 9, 2018
    Assignee: BRISTOL-MYERS QUIBB COMPANY
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20180002429
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: July 11, 2017
    Publication date: January 4, 2018
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ST2 ANTIGEN BINDING PROTEINS
    Publication number: 20170267769
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 21, 2017
    Applicant: Amgen Inc.
    Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9738721
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: August 22, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20170218076
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9663571
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: May 30, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Oncostatin M receptor antigen binding proteins
    Patent number: 9593163
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 14, 2017
    Assignee: Kiniksa Pharmaceuticals, Ltd.
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20170008958
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 12, 2017
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • ST2 ANTIGEN BINDING PROTEINS
    Publication number: 20170002079
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Application
    Filed: June 10, 2016
    Publication date: January 5, 2017
    Applicant: Amgen Inc.
    Inventors: Dirk E. SMITH, Ian FOLTZ, Chadwick T. KING, Ai Ching LIM, Rutilio CLARK, Michael R. COMEAU, Randal R. KETCHEM, Donghui SHI, Xiaoshan MIN, Zhulun WANG
  • INHIBITORS OF TYPE 2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
    Publication number: 20160297869
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Application
    Filed: March 15, 2016
    Publication date: October 13, 2016
    Inventors: Yan CHEN, Elena GETMANOVA, Martin C. WRIGHT, Alan S. HARRIS, Ai Ching LIM, Jochem GOKEMEIJER, Lin SUN, Michael WITTEKIND
  • IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS
    Publication number: 20160251443
    Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to the identification of neutralizing determinants on IL-17 Receptor A (IL-17RA or IL-17R) and antibodies that bind thereto. Aspects of the invention also include antibodies that compete for binding with the IL-17RA neutralizing antibodies described herein.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 1, 2016
    Inventors: Joel E. Tocker, Jacques J. Peschon, David Fitzpatrick, James F. Smothers, Christopher Mehlin, Ai Ching Lim
  • ST2 antigen binding proteins
    Patent number: 9382318
    Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 5, 2016
    Assignee: Amgen Inc.
    Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
  • METHODS AND COMPOSITIONS RELATING TO ANTI-IL-21 RECEPTOR ANTIBODIES
    Publication number: 20160176971
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Application
    Filed: March 1, 2016
    Publication date: June 23, 2016
    Applicant: Amgen Inc.
    Inventors: Marc A. GAVIN, Ai Ching LIM
  • ONCOSTATIN M RECEPTOR ANTIGEN BINDING PROTEINS
    Publication number: 20160137739
    Abstract: The invention provides anti-oncostatin M receptor-? (OSMR) antigen binding proteins. e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. OSMR antigen binding proteins interfere with binding of OSM and/or IL-31 to OSMR. In some embodiments, anti-OSMR antigen binding proteins are useful tools in studying diseases and disorders associated with OSMR and are particularly useful in methods of treating diseases and disorders associated with OSMR and binding of OSM and/or IL-31 to OSMR.
    Type: Application
    Filed: May 30, 2014
    Publication date: May 19, 2016
    Inventors: Heather A. Arnett, Sabine S. Escobar, Chadwick T. King, Ai Ching Lim, Saravanakumar Narayanan, Paul H. Weinreb, Nels E. Pederson
  • Inhibitors of type 2 vascular endothelial growth factor receptors
    Patent number: 9328157
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 3, 2016
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Compositions relating to anti-IL-21 receptor antibodies
    Patent number: 9309318
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 12, 2016
    Assignee: Amgen, Inc.
    Inventors: Marc A. Gavin, Ai Ching Lim